Anti-nonspecific protein adsorption polypeptide with controllable enzyme degradation, monomer and preparation method thereof
The anti-nonspecific protein adsorption peptides with controllable enzyme degradation are prepared through side chain-protected dipeptide monomer condensation reaction, which solves the problem of metabolic pathways of existing materials in organisms, realizes enzyme degradation and functional regulation of peptides, and improves adsorption capacity and drug delivery efficiency.
Patent Information
- Application Number
- CN201610915684.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2016-10-20
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2036-10-20
AI Technical Summary
Existing anti-nonspecific protein adsorption materials, such as polyethylene glycol and zwitterionic polymers, cannot enter normal metabolic pathways in the organism, resulting in abnormal cell death and inflammation in the body, and it is difficult to control the rate of enzyme degradation and molecular weight.
The dipeptide monomer containing protected carboxyl groups and protected amino groups on the side chain is prepared by condensation reaction to prepare non-specific protein adsorption polypeptides with controllable enzyme degradation. The reaction is regulated by racemic inhibitors and blocking agents to achieve enzymatic degradation of the polypeptide. and functional modification.
Controllable enzyme degradation of polypeptides is achieved, side effects in drug delivery process are reduced, anti-nonspecific protein adsorption ability is improved, and the time requirements for drug delivery are met by regulating molecular weight and half-life of enzyme degradation.
Smart Images

Figure CN106565824B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a polypeptide and a preparation method thereof, in particular to a polypeptide resistant to non-specific protein adsorption and a preparation method thereof. Background Art
[0002] Nonfouling materials are a special type of biocompatible materials proposed in the past decade. They were listed as a new generation of biocompatible materials by Buddy D. Ratner, a member of the American Academy of Engineering, in the 2004 Annu. Rev. Biomed. Eng. It prevents the adsorption of protein molecules through interaction with water, thereby avoiding further biochemical reactions, such as blood coagulation in the blood. Through continuous in-depth research on materials against nonspecific protein adsorption, it is found that nonspecific protein adsorption materials can not only effectively prevent the occurrence of coagulation processes in blood contact systems, but also can be applied to prevent human rejection and removal reactions, bacterial adsorption, and various biofouling phenomena caused by the adsorption of biomacromolecules at a wide range of solid-liquid interfaces, including the formation of biofilms, the growth of algae, and the growth of shellfish adsorbed on the surface. Preventing bacterial adsorption and the formation of biofilms alone can buy valuable time to prevent infections caused by biological implants. For example, Bausch and Lomb contact lens wash in 2007 became a global crisis because it failed to prevent the growth of biofilms on contact lenses.
[0003] The existing anti-nonspecific protein adsorption materials are mainly represented by polyethylene glycol (PEG), but polyethylene glycol has obvious defects, including: 1) PEG will naturally oxidize under the conditions of oxygen and transition metal ions, and the terminal hydroxyl group will be oxidized to aldehyde by alcohol dehydrogenase in the body, and the aldehyde group can easily react with protein or other molecules containing amino groups. 2) The protein non-adsorption of PEG has certain requirements on the molecular arrangement. Too tight or large molecular weight will lose protein non-adsorption. 3) The hydrodynamic radius of PEG molecules is large, and its apparent volume is about 5 to 10 times the volume of water-soluble protein molecules of similar molecular weight, which has a great impact on the volume of modified biological molecules. 4) After PEG is fixed to one end of the molecule, the functionalization of the other end also brings great difficulties. If a higher density of activatable functional groups is introduced, the nonfouling characteristics will be lost due to their introduction. If there are too few, it will become very difficult to fix another functional molecule. Therefore, polyethylene glycol-based protein non-adsorption materials have encountered great difficulties in implantation in the body, nano-targeted drug delivery and other fields.
[0004] On the other hand, from the perspective of bionics, phosphorylcholine is a functional group that is widely present in the human body, so it has long been studied as a biomaterial, especially for applied development. Studies have found that after a layer of polymer coating containing phosphorylcholine groups is applied to the surface of the material, the blood compatibility of the material is greatly improved, thereby effectively reducing the occurrence of coagulation. Since the 1970s and 1980s, phosphorylcholine analogs have been continuously synthesized. The earliest one was 2-methacrylate glycol phosphorylcholine (MPC) synthesized in 1977, but the synthesis efficiency is still low. Therefore, the concept of phosphorylcholine base is extended to other zwitterions. Zwitterionic materials such as sulfon-ammonium (such as sulfonate betaine methacrylate (SBMA) and carboxylate-ammonium (such as carboxylate betaine methacrylate (CBMA)) gradually appeared. Sulfon-ammonium and carboxylate-ammonium materials not only have good nonfouling properties like phosphorylcholine materials, but also their monomer synthesis is simple, efficient and stable. In particular, carboxylate-ammonium nonfouling materials not only have good resistance to protein molecule adsorption, but also have been shown to have a large number of functional groups that can be used to fix ligands. On the other hand, from a synthetic point of view, the two-step synthesis can more conveniently avoid the problem of solubility selection and is easier to form copolymers with other low-polarity monomers.
[0005] However, both polyethylene glycol and zwitterionic polymers have an important defect in the body, especially in the human body, that is, they cannot enter the normal metabolic pathway of the human body and are eliminated from cells and the body through degradation, which often leads to abnormal cell death and inflammation in the body. Therefore, there is an urgent need to develop a degradable anti-nonspecific protein adsorption material. The present invention discloses a new anti-nonspecific protein adsorption material and a synthesis method based on this demand. Summary of the invention
[0006] The technical problem to be solved by the present invention is to provide a polypeptide with controllable enzyme degradation and resistance to non-specific protein adsorption, a monomer thereof and a preparation method thereof.
[0007] The technical solution adopted by the present invention to solve the above technical problems is:
[0008] The dipeptide monomer containing a protected carboxyl group and a protected amino group in the side chain of the present invention has a structure as shown in the following formula I or formula II:
[0009]
[0010] The preparation method of the above-mentioned dipeptide monomer is: condense the first reactant and the second reactant, and then hydrolyze to obtain the dipeptide monomer; the first reactant is glutamic acid protected by amino group and side chain carboxyl group, or aspartic acid protected by amino group and side chain carboxyl group; the second reactant is lysine protected by carboxyl group and omega amino group.
[0011] Furthermore, the reaction system of the condensation reaction in the above preparation method of the present invention comprises a racemization inhibitor.
[0012] The dipeptide monomer containing a protected carboxyl group and a protected amino group in the side chain of the present invention has a structure as shown in any one of the following formulas III to VI:
[0013]
[0014]
[0015] Further, the preparation method of the dipeptide monomer of the present invention is:
[0016] The third reactant and the fourth reactant are subjected to a condensation reaction and hydrolyzed to obtain the dipeptide monomer, wherein the third reactant is alpha-amino-protected and carboxyl-protected glutamic acid, or alpha-amino-protected and carboxyl-protected aspartic acid; and the fourth reactant is carboxyl-protected and alpha-amino-protected lysine, or carboxyl-protected and omega-amino-protected lysine.
[0017] Furthermore, the reaction system of the condensation reaction of the present invention comprises a racemization inhibitor.
[0018] The non-specific protein adsorption resistant polypeptide with controllable enzymatic degradation of the present invention has a structure as shown in any one of Formula VII to Formula XIV:
[0019]
[0020]
[0021]
[0022] In the above formulae, m and n represent the polymerization degree of the monomers, respectively, and m and n are integers greater than or equal to 0, and m+n>0.
[0023] Furthermore, the structural formula of the polypeptide of the present invention is shown in any one of Formula XV to Formula XXX:
[0024]
[0025]
[0026]
[0027]
[0028]
[0029] Among them, R1 is a carboxylic acid group containing a selective reactive group for functional modification after deprotection, and R2 is an amino group containing a selective reactive group for functional modification after deprotection.
[0030] Furthermore, R1 described in the present invention is a lipoic acid group, or a cysteine group connected to a carboxyl group on cysteine; R2 is a cysteamine group, or a cysteine group connected to an amino group on cysteine.
[0031] The preparation method of the polypeptide of the present invention comprises: subjecting the first monomer and / or the second monomer to a condensation polymerization reaction, and subjecting the condensation polymer to a deprotection group treatment to obtain the polypeptide;
[0032] The first monomer has a structure as shown in Formula I or Formula II, and the second monomer has a structure as shown in Formula III, Formula IV, Formula V or Formula VI:
[0033]
[0034]
[0035]
[0036] Furthermore, the reaction system of the polycondensation reaction of the present invention contains an amino-terminal capping agent or a carboxyl-terminal capping agent.
[0037] Furthermore, the amino-terminal capping agent of the present invention is a carboxylic acid containing a thiol group after deprotection.
[0038] Furthermore, the amino-terminal capping agent of the present invention is lipoic acid or a cysteine derivative, and the cysteine derivative contains an amino group protected by a benzyloxycarbonyl group and a thiol group protected by a trityl group.
[0039] Furthermore, the carboxyl end-capping agent of the present invention is an amine containing a thiol group after deprotection.
[0040] Furthermore, the carboxyl end-capping agent of the present invention is cysteamine protected by mercaptotriphenylmethyl, or cysteine protected by carboxybenzyl and mercaptotriphenylmethyl.
[0041] Compared with the prior art, the present invention has the following beneficial effects:
[0042] (1) Whether it is the existing polyethylene glycol or zwitterionic polymers, the anti-nonspecific protein adsorption materials have an important defect in the body, especially in the human body, that is, they cannot enter the normal metabolic pathway of the human body and are excreted from cells and outside the body through degradation, which often leads to abnormal cell death and inflammation in the body. Therefore, there is an urgent need to develop a degradable anti-nonspecific protein adsorption material that can be excreted from cells and outside the body through normal metabolic pathways. The anti-nonspecific protein adsorption polypeptide of the present invention can be degraded into short peptides or amino acids by enzymes, and the aggregation of the anti-nonspecific protein adsorption material in cells or in the body can be eliminated through normal amino acid metabolic pathways, thereby reducing the side effects of the anti-nonspecific protein adsorption material during the use of drug delivery, etc.
[0043] (2) Due to the problems of competitive polymerization rate and condensation reaction probability in the copolymerization product of amino acid monomers with positively charged side chains and negatively charged side chains after deprotection, the ratio of amino acid residues with positively charged side chains and negatively charged side chains is easily unequal in the target product zwitterionic polypeptide, and the amino acid residues with positively charged side chains or negatively charged side chains overlap, so that the target product cannot obtain a zwitterionic polypeptide with repeated positive and negative charges. The present invention uses the condensation of dipeptide monomers with protected carboxyl groups and protected amino groups on the side chains and the subsequent deprotection to prepare a polypeptide with perfect repeated alternation of positive and negative charges, thereby improving the polypeptide's resistance to nonspecific protein adsorption and having the enzymatic degradation ability of the polypeptide.
[0044] (3) Since the degradation rate of normal polypeptide structures in vivo is difficult to control, they can generally be decomposed in a short time, thus losing the ability to resist non-specific protein adsorption. By means of the condensation polymerization of amino acid monomers modified with both protected carboxyl and protected amino molecules on the side chains and the subsequent deprotection, polypeptides with positive and negative charges on the side chains are prepared, which are not degraded by enzymes while ensuring the ability of the polypeptides to resist non-specific protein adsorption. Moreover, by further condensation polymerization of dipeptide monomers containing protected carboxyl and protected amino molecules on the side chains and amino acid monomers containing both protected carboxyl and protected amino molecules on the side chains and the subsequent deprotection at different ratios, polypeptides resistant to non-specific protein adsorption with different enzymatic degradation half-lives are obtained, thereby achieving the regulation of the enzymatic degradation ability of polypeptides resistant to non-specific protein adsorption and meeting the time requirements corresponding to applications such as drug delivery.
[0045] (4) Since the anti-nonspecific protein adsorption polypeptide is only obtained by the condensation of the dipeptide monomer containing protected carboxyl and protected amino groups on the side chain and the amino acid monomer containing protected carboxyl and protected amino groups on the side chain, the molecular weight of the polypeptide formed by the condensation is difficult to control, which poses certain difficulties for the specific application that requires the molecular weight to be controlled. Therefore, the molecular weight of the target polypeptide can be regulated by adding the ratio of the capping agent to the monomer; and the functionalized modification groups on the capping agent can be used to modify different proteins, polypeptides and other polymers, as well as the surfaces of different materials.
[0046] Therefore, the polypeptide with controllable enzyme degradation and resistance to nonspecific protein adsorption of the present invention has broad application prospects in the research of drug / gene carriers and in vivo degradable hydrogels. BRIEF DESCRIPTION OF THE DRAWINGS
[0047] Figure 1 is the nuclear magnetic resonance spectrum of the polypeptide synthesized in Example 1;
[0048] Figure 2 This is the enzymatic degradation profile of the polypeptide synthesized in Example 1, and the enzymatic degradation time is about 20 min;
[0049] Figure 3 is the NMR spectrum of the mixed polypeptide synthesized in Example 2;
[0050] Figure 4 This is the enzymatic degradation profile of the mixed polypeptide synthesized in Example 2, and the enzymatic degradation time is about 25 min;
[0051] Figure 5 is the NMR spectrum of the mixed polypeptide synthesized in Example 3;
[0052] Figure 6 This is the enzymatic degradation profile of the mixed polypeptide synthesized in Example 3, and the enzymatic degradation time is about 35 min;
[0053] Figure 7 is the NMR spectrum of the mixed polypeptide synthesized in Example 4;
[0054] Figure 8 This is the enzymatic degradation profile of the mixed polypeptide synthesized in Example 4, and the enzymatic degradation time is about 55 min;
[0055] Fig. 9 is the NMR spectrum of the polypeptide synthesized in Example 5;
[0056] Fig.10 is the 24h enzyme degradation profile of the polypeptide synthesized in Example 5, indicating that the polymer cannot be degraded within 24h;
[0057] Fig.11is the molecular weight of different polypeptide products obtained by adjusting the feed ratio of monomer to end-capping agent lipoic acid in Example 6;
[0058] Fig.12 is a graph showing the test results of the anti-nonspecific protein adsorption performance of the polypeptide synthesized in Example 7;
[0059] Fig.13 is a graph showing the test results of the anti-nonspecific protein adsorption performance of the polypeptide synthesized in Example 8;
[0060] Fig.14 is a graph showing the test results of the anti-nonspecific protein adsorption performance of the polypeptide synthesized in Example 9;
[0061] Fig.15 This is a graph showing the test results of the anti-nonspecific protein adsorption performance of the polypeptide synthesized in Example 10. DETAILED DESCRIPTION
[0062] The present invention utilizes different deprotection conditions of the side chain and the amino and carboxyl groups forming the main chain, forms a dipeptide with all amino and carboxyl groups protected by condensation of the amino and carboxyl groups, and then removes the protecting groups on the amino and carboxyl groups forming the main chain, while the side chains are still in a protected state to be polycondensed glutamic acid and lysine dipeptide (i.e., the first monomer and the second monomer); and utilizes the polycondensation of the amino and carboxyl groups forming the main chain to form a polypeptide intermediate with the side chains still in a protected state, and obtains the target zwitterionic polypeptide after deprotection and separation. In the polycondensation process, a capping agent can be added or not added to obtain zwitterionic polypeptides of different molecular weights containing or not containing selective reactive groups for functional modification; and the molecular weight can be controlled by controlling the ratio of the capping agent to the dipeptide monomer.
[0063] In the present invention, condensation, polycondensation, and terminalization all utilize the amidation condensation reaction of amino and carboxyl groups. In the presence of a condensing agent, condensation, polycondensation, and terminalization have the same chemical reaction characteristics, and the selective deprotection involved in the present invention is a mature method in peptide synthesis chemistry. Therefore, those skilled in the art can know that different condensation intermediates and polycondensation products are formed due to changes in the positions of amino and carboxyl groups. For this reason, the following does not repeat the embodiments due to changes in the positions of amino and carboxyl groups.
[0064] The following is an exemplary description of the synthesis of the polypeptide with controllable enzymatic degradation and resistance to non-specific protein adsorption of the present invention using synthetic routes 1 and 2. It should be noted that the preparation of the polypeptide with controllable enzymatic degradation and resistance to non-specific protein adsorption of the present invention is not limited to these two synthetic routes.
[0065]
[0066] Wherein, the structural formula of the first monomer is shown in the following formula I or formula II:
[0067]
[0068] The structural formula of the second monomer is shown in any one of the following formulas III to VI:
[0069]
[0070]
[0071] In the above synthetic route 1 and the collectively referred to route 2, the first monomer and the second monomer may exist simultaneously or only one of them may exist, that is, one of m and n may be 0, but m and n are not 0 at the same time.
[0072] The following is an exemplary description of the preparation method of the polypeptide with controllable enzymatic degradation and resistance to non-specific protein adsorption of the present invention, which may preferably include the following parts:
[0073] (I) Condensation synthesis of side chain protected dipeptide monomers
[0074] Through the condensation of glutamic acid and lysine with different protecting groups, such as γ-benzyl-N-tert-butyloxycarbonyl-L-glutamic acid and N ε -benzyloxycarbonyl-α-tert-butyl-L-lysine, and through selective deprotection, a dipeptide with side chains protected by benzyl and benzyloxycarbonyl is obtained, and separated and purified for the next step of polycondensation. The advantage of this method is that it can avoid the direct use of two side chain protected amino acids (such as γ-benzyl-L-glutamic acid and N ε -benzyloxycarbonyl--L-lysine) is mixed and polycondensed, resulting in uneven distribution of positively and negatively charged amino acid residues in the polypeptide, thereby affecting the ability to resist nonspecific protein adsorption.
[0075] (II) Polycondensation reaction
[0076] In the present invention, the end-capping agent may or may not be added during the polycondensation, and the two situations correspond to the formation of polypeptides with end groups and without end groups, respectively. The specific method is: under room temperature, the side chain protected dipeptide monomer (only one of the first monomer and the second monomer is added or both are added at the same time) and the condensation agent are dissolved in an organic solvent, preferably a racemization inhibitor can be added to the organic solvent, and an end-capping agent can be further added to form a polypeptide intermediate after a closed reaction. The addition of a racemization inhibitor can inhibit the generation of racemization, ensuring that the final product, the anti-nonspecific protein adsorption polypeptide, can be recognized and degraded by the enzyme. If the end-capping molecule is added during the feeding, and the molar ratio of the end-capping molecule to the dipeptide monomer is controlled, the molecular weight of the prepared polypeptide can be easily controlled, and one end of the polypeptide can be provided with a functional group that can further react chemically.
[0077] (III) Deprotection
[0078] The intermediate is dissolved in a deprotection reaction solution (e.g., a mixed solution of trifluoroacetic acid and 33 wt.% hydrobromic acid and acetic acid, the volume ratio of trifluoroacetic acid and 33 wt.% hydrobromic acid and acetic acid being 1:1), and reacted at room temperature for 2-6 hours to deprotect the polypeptide, thereby removing the benzyloxycarbonyl and benzyl protection of the polypeptide; and then a precipitant (e.g., anhydrous ether or petroleum ether) is added to the reaction solution for precipitation, so that the product is easy to separate.
[0079] (IV) Product Purification
[0080] The polypeptide with side chain protection removed (e.g., benzyloxycarbonyl and benzyl protection removed) is dissolved in water, neutralized with saturated sodium bicarbonate solution, and the entire solution is transferred into a dialysis bag with a molecular weight cutoff of 1 kDa for dialysis or separated with a centrifugal separation tube to remove small molecules, and a white powder solid product is obtained after freeze-drying. The separation and purification of small molecules of the polypeptide can ensure the removal of unreacted small molecules other than the target polypeptide and solvent molecules during the reaction.
[0081] In the following specific examples, the evaluation method of the polypeptide with controllable enzymatic degradation resistance to non-specific protein adsorption of the present invention is as follows:
[0082] (1) Enzymatic hydrolysis
[0083] Take 9 2mL centrifuge tubes, add 1mL of 0.1M NH4HCO3 solution containing 3mg / mL target peptide to each tube, and then add 100μL of 0.1M NH4HCO3 solution containing 1mg / mL trypsin, shake well, and perform enzymolysis at 37℃ and 500rpm. At different time points during the enzymolysis process, put the enzymolysis solution into boiling water and cook for 8-10min to fully inactivate the activity of trypsin. In addition, treat the 0.1M NH4HCO3 solution containing only 1mg / mL trypsin and the 0.1M NH4HCO3 solution containing only 3mg / mL target peptide with the above enzymolysis method as two control samples.
[0084] (2) Gel Permeation Chromatography (GPC) Analysis
[0085] GPC was used to monitor the enzyme reaction process. GPC detection conditions: mobile phase was 0.1M NH4HCO3, flow rate was 0.5mL / min; column temperature was set at 45℃, injection volume was 100μL. Polyoxyethylene (PEO) of different molecular weights was used as standard sample.
[0086] (3) Material resistance to nonspecific protein adsorption
[0087] The gold sheet was washed with ethanol and deionized water, dried, and the process was repeated twice; then it was placed in a UV cleaner for cleaning for 20 minutes. It was washed again with ethanol and deionized water twice, dried, and immersed in 2 mg / mL phosphate buffer (PBS pH 7.4) containing thiol-terminated target polypeptides for incubation for 48 hours. It was taken out again, rinsed with deionized water for another 5 times, and dried. The nonspecific protein adsorption of the obtained gold sheet with polypeptide self-assembled monolayer (SAMs) was measured by HRP-labeled sheep anti-human immunoglobulin (anti-IgG / HRP) and fibrinogen (fibrinogen, Fg) combined with HRP-labeled fibrinogen antibody. The TCPS surface was used as a control, and the amount of protein adsorbed on the TCPS surface was set to 100%. The detailed operation process is as follows: the sample to be tested was first incubated with anti-IgG (1μg / mL) or Fg (10μg / mL) for 20 minutes, and then rinsed with PBS to remove all unadsorbed proteins. For Fg, it is also necessary to use HRP-labeled fibrinogen (anti-Fg / HRP) antibody to determine its adsorption amount. The sample adsorbed with Fg was then incubated with 10μg / mL HRP-labeled fibrinogen antibody (anti-Fg / HRP) for 20 minutes, and then rinsed with PBS to remove all unadsorbed proteins. After that, all samples to be tested and TCPS controls were placed in a 24-well plate, and 1mL of 1mg / mL o-phenylenediamine (OPD) citric acid buffer solution (0.1M, pH 5.0, containing 0.03% hydrogen peroxide) was injected into each well. After 10-20 minutes of color development, 1mL of 2N H2SO4 was added to each well to quench the enzyme activity. The absorbance of each well at 492nm was measured by an enzyme reader, and the relative amount of protein adsorption was calculated per unit area.
[0088] The following is a detailed description of the method for preparing the polypeptide having controllable enzymatic degradation and resistance to non-specific protein adsorption of the present invention with specific examples.
[0089] Embodiment 1:
[0090] 1) Polycondensation
[0091] Take 200 mg (0.4 mmol) of the first monomer (structural formula as shown in Formula I), add 115 mg (0.6 mmol) of 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC.HCl) and 81 mg (0.6 mmol) of 1-hydroxybenzotriazole (HOBt). After adding 2 mL of anhydrous N, N-diformamide (DMF) to the system, seal it with a rubber stopper, introduce nitrogen bubbling for 30 minutes, and then seal it at room temperature for 48 hours. After the reaction is completed, add about 18 mL of anhydrous ether precipitation to the reaction system, let it stand for about 20 minutes, and then pour off the solvent to obtain an oily zwitterionic polypeptide with alternating glutamic acid and lysine residues without deprotection groups.
[0092] 2) Deprotection
[0093] After the above oil is completely dissolved with about 2 mL of trifluoroacetic acid (TFA), add about 2 mL of 33% (33wt.%) hydrobromic acid / acetic acid (HBr / HOAc) solution for deprotection. The reaction system will become turbid in about 1 hour. After about 2 hours of reaction, add 25 mL of anhydrous ether to the reaction system to precipitate the product. After decanting the solution, add about 10 mL of anhydrous ether and wash again. After the deprotected polypeptide is completely dissolved with distilled water, neutralize it with saturated NaHCO3 solution to neutrality, and then transfer the solution to a dialysis bag with a molecular weight cutoff of 1000 (MWCO=1000) and dialyze for 2-3 days. The obtained solution is frozen and vacuum dried to obtain a white solid product, which is a zwitterionic polypeptide (target polypeptide) (structural formula is shown in Formula VII, n:m=0:1). The nuclear magnetic resonance (NMR) of the product ( 1 HNMR) spectrum Figure 1 shown. 1 HNMR (D2O, 400MHz): δ1.20-1.50 2H, 1.51-1.592H, 1.65-2.06 4H, 2.08-2.36 2H, 2.90-2.94 2H, 3.95-4.23 2H.
[0094] 3) Degradation time of synthetic peptides resistant to nonspecific protein adsorption
[0095] The polypeptide (target polypeptide) prepared in Example 1 was hydrolyzed according to the enzymatic hydrolysis method described in the evaluation method above. At 0 minutes, 5 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 24 hours and other time points during the enzymatic hydrolysis process, the enzymatic solution was placed in boiling water and boiled for 8-10 minutes to fully inactivate the enzyme activity. In addition, 100 μL of a 0.1M NH4HCO3 solution containing only 1 mg / mL of trypsin and 1 mL of a 0.1M NH4HCO3 solution containing only 3 mg / mL of the target polypeptide were treated in the same manner to obtain two control samples. The GPC spectrum measured by gel permeation chromatography (GPC) analysis is shown in FIG. Figure 2 ,from Figure 2 It can be seen that the polypeptide synthesized in Example 1 has been partially hydrolyzed in about 5 minutes, but has not been completely hydrolyzed in 10 minutes, but has been basically completely hydrolyzed in about 30 minutes. Therefore, it can be considered that the complete enzymatic degradation time of the polypeptide should be about 20 minutes.
[0096] Embodiment 2:
[0097] 1) Polycondensation
[0098] Take 100 mg (0.2 mmol) of the first monomer (whose structural formula is shown in Formula I) and 20 mg (0.04 mmol) of the second monomer (whose structural formula is shown in Formula III), add 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC.HCl) (86.4 mg, 0.45 mmol) and 1-hydroxy-7-azobenzotriazole (HOAt) (61.3 mg, 0.45 mmol), and 0.004 mmol of cysteine protected by aminobenzyloxycarbonyl-protected mercaptotriphenylmethyl-protected end-capping agent. After adding about 2 mL of anhydrous DMF to the system, seal it with a rubber stopper, bubbling nitrogen for 30 minutes, and then reacting at room temperature for 24 hours. After the reaction is completed, add about 18 mL of anhydrous ether to the reaction system for precipitation, let it stand for about 20 minutes, and then pour off the solvent to obtain an oily polypeptide without deprotection (the molar ratio of the first monomer to the second monomer is 5:1).
[0099] 2) Deprotection
[0100] After the above oil is completely dissolved with about 2 mL of trifluoroacetic acid (TFA), add about 2 mL of 33% (33wt.%) hydrobromic acid / acetic acid (HBr / HOAc) solution for deprotection. The reaction system will become turbid in about 1 hour. After reacting for about 2 hours, add 25 mL of anhydrous ether to the reaction system to precipitate the product. After decanting the solution, add about 10 mL of anhydrous ether and wash again. After the deprotected polypeptide is completely dissolved with distilled water, neutralize it with saturated NaHCO3 solution to neutrality, and then transfer the solution to a dialysis bag with a molecular weight cutoff of 1000 (MWCO=1000) and dialyze for 2-3 days. The obtained solution is frozen and vacuum dried to obtain a white solid product. The product is a zwitterionic polypeptide (target polypeptide) (the structural formula is shown in Formula VII, n:m=1:5). The product 1 HNMR spectrum Figure 3 shown.
[0101] 3) Degradation time of synthetic peptides resistant to nonspecific protein adsorption
[0102] The polypeptide (target polypeptide) prepared in this example was hydrolyzed according to the enzymatic hydrolysis method described in the evaluation method above. At 0 minutes, 10 minutes, 20 minutes, 30 minutes, 1 hour, 2 hours, etc., the reaction solution was placed in boiling water and boiled for 8-10 minutes to fully inactivate the enzyme activity. In addition, 100 μL of a 0.1M NH4HCO3 solution containing only 1 mg / mL of trypsin and 1 mL of a 0.1M NH4HCO3 solution containing only 3 mg / mL of the target polypeptide were treated with the above method as control samples. The GPC spectrum measured by gel permeation chromatography (GPC) analysis is shown in FIG. Figure 4 , the enzyme degradation time is about 20min.
[0103] Embodiment 3:
[0104] 1) Polycondensation
[0105] Take 100 mg (0.2 mmol) of the first monomer (whose structural formula is shown in Formula I) and 100 mg (0.2 mmol) of the second monomer (whose structural formula is shown in Formula III), add dicyclohexylcarbodiimide (DCC) (154.7 mg, 0.75 mmol) and 1-hydroxybenzotriazole (HOBt) (101.2 mg, 0.75 mmol), and 0.004 mmol of cysteine protected by aminobenzyloxycarbonyl-protected mercaptotriphenylmethyl-protected end-capping agent. After adding about 2 mL of anhydrous DMF to the system, seal it with a rubber stopper, bubbling nitrogen for 30 minutes, and then reacting at room temperature for 48 hours. After the reaction is completed, add about 18 mL of anhydrous ether to the reaction system for precipitation, let it stand for about 20 minutes, and then pour off the solvent to obtain an oily undeprotected polypeptide (the molar ratio of the first monomer to the second monomer is 1:1).
[0106] 2) Deprotection
[0107] After the above oil is completely dissolved with about 2 mL of trifluoroacetic acid (TFA), about 2 mL of 33% (33 wt.%) hydrobromic acid / acetic acid (HBr / HOAc) solution is added for deprotection. The reaction system will become turbid in about 1 hour. After about 2 hours of reaction, 25 mL of anhydrous ether is added to the reaction system to precipitate the product. After decanting the solution, about 10 mL of anhydrous ether is added to wash again. After the deprotected polypeptide is completely dissolved with distilled water, it is neutralized to neutrality with a saturated NaHCO3 solution, and then the solution is transferred to a dialysis bag with a molecular weight cutoff of 1000 (MWCO=1000) and dialyzed for 2-3 days. The obtained solution is frozen and vacuum dried to obtain a white solid product, which is a zwitterionic polypeptide (the structural formula is shown in Formula VII, n:m=1:1). 1 The HNMR spectrum is Figure 5 .
[0108] 3) Degradation time of synthetic peptides resistant to nonspecific protein adsorption
[0109] The polypeptide (target polypeptide) prepared in this example was hydrolyzed according to the enzymatic hydrolysis method described in the aforementioned evaluation method. At each time point such as 0 minutes, 10 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, and 2 hours, the reaction solution was placed in boiling water and boiled for 8-10 minutes to fully inactivate the enzyme activity. In addition, 100 μL of a 0.1M NH4HCO3 solution containing only 1 mg / mL of trypsin and 1 mL of a 0.1M NH4HCO3 solution containing only 3 mg / mL of the target polypeptide were treated with the above method as control samples. The GPC spectrum measured by gel permeation chromatography (GPC) analysis is shown in FIG. Figure 6 , the enzyme degradation time is about 35min.
[0110] Embodiment 4:
[0111] 1) Polycondensation
[0112] Take 100 mg (0.2 mmol) of the first monomer (whose structural formula is shown in Formula I) and 200 mg (0.4 mmol) of the second monomer (whose structural formula is shown in Formula III) (molar ratio 1:2), add dicyclohexylcarbodiimide (DCC) (233 mg, 1.13 mmol) and 1-hydroxy-7-azobenzotriazole (HOAt) (153.8 mg, 1.13 mmol), and 0.004 mmol of cysteine protected by aminobenzyloxycarbonyl-protected mercaptotriphenylmethyl-protected end-capping agent. After adding about 3 mL of anhydrous DMF to the system, seal it with a rubber stopper, bubbling nitrogen for 30 minutes, and then reacting at room temperature for 36 hours. After the reaction is completed, add about 25 mL of anhydrous ether to the reaction system for precipitation, let it stand for about 20 minutes, and then pour off the solvent to obtain an oily undeprotected polypeptide (the molar ratio of the first monomer to the second monomer is 1:2).
[0113] 2) Deprotection
[0114] After the above oil is completely dissolved with about 2 mL of trifluoroacetic acid (TFA), about 2 mL of 33% (33 wt.%) hydrobromic acid / acetic acid (HBr / HOAc) solution is added for deprotection. The reaction system will become turbid in about 1 hour. After about 2 hours of reaction, 25 mL of anhydrous ether is added to the reaction system to precipitate the product. After decanting the solution, about 10 mL of anhydrous ether is added to wash again. After the deprotected polypeptide is completely dissolved with distilled water, it is neutralized to neutrality with a saturated NaHCO3 solution, and then the solution is transferred to a dialysis bag with a molecular weight cutoff of 1000 (MWCO=1000) and dialyzed for 2-3 days. The obtained solution is frozen and vacuum dried to obtain a white solid product, which is a zwitterionic polypeptide (the structural formula is shown in Formula VII, n:m=1:2). 1 The HNMR spectrum is Figure 7 .
[0115] 3) Degradation time of synthetic peptides resistant to nonspecific protein adsorption
[0116] The polypeptide (target polypeptide) prepared in this example was hydrolyzed according to the enzymatic hydrolysis method described in the evaluation method above. At 0 minutes, 50 minutes, 1 hour, 2 hours, etc., the reaction solution was placed in boiling water and boiled for 8-10 minutes to fully inactivate the enzyme activity. In addition, 100 μL of a 0.1M NH4HCO3 solution containing only 1 mg / mL of trypsin and 1 mL of a 0.1M NH4HCO3 solution containing 3 mg / mL of the target polypeptide were treated in the above manner as control samples. The GPC spectrum measured by gel permeation chromatography (GPC) analysis is shown in FIG. Figure 8 , the enzyme degradation time is about 55min.
[0117] Embodiment 5:
[0118] 1) Polycondensation
[0119] Take 200 mg (0.4 mmol) of the second monomer (whose structural formula is shown in Formula III), add EDC.HCl (153 mg, 0.8 mmol) and HOBt (108 mg, 0.8 mmol). After adding about 2 mL of anhydrous DMF to the system, seal it with a rubber stopper, bubble nitrogen for 30 minutes, and then react at room temperature for 40 hours. After the reaction is completed, add about 18 mL of anhydrous ether to the reaction system for precipitation. After standing for about 20 minutes, pour off the solvent to obtain an oily polypeptide polymerized from the second monomer without deprotection.
[0120] 2) Deprotection
[0121] After the above oil is completely dissolved with about 2 mL of trifluoroacetic acid (TFA), about 2 mL of 33% (33 wt.%) hydrobromic acid / acetic acid (HBr / HOAc) solution is added for deprotection. The reaction system will become turbid in about 1 hour. After about 3 hours of reaction, 25 mL of anhydrous ether is added to the reaction system to precipitate the product. After decanting the solution, about 10 mL of anhydrous ether is added to wash again. After the deprotected polypeptide is completely dissolved with distilled water, it is neutralized to neutrality with a saturated NaHCO3 solution, and then the solution is transferred to a dialysis bag with a molecular weight cutoff of 1000 (MWCO=1000) and dialyzed for 2-3 days. The obtained solution is frozen and vacuum dried to obtain a white solid product, which is a zwitterionic polypeptide (the structural formula is shown in Formula VII, n:m=1:0). 1 The HNMR spectrum is Fig. 9 . 1HNMR (D2O, 400MHz): δ1.20-1.50 2H, 1.51-1.59 2H, 1.65-2.06 4H, 2.08-2.362H, 2.90-2.94 2H, 3.95-4.23 2H. Fig. 9 The polypeptide structure shown.
[0122] 3) Degradation time of synthetic peptides resistant to nonspecific protein adsorption
[0123] The polypeptide (target polypeptide) prepared in this example was hydrolyzed according to the enzymatic hydrolysis method described in the evaluation method above. At 0 hours, 1 hour, 4 hours, 8 hours, 24 hours and other time points, the reaction solution was placed in boiling water and boiled for 8-10 minutes to fully inactivate the enzyme activity. In addition, 100 μL of a 0.1M NH4HCO3 solution containing only 1 mg / mL of trypsin and 1 mL of a 0.1M NH4HCO3 solution containing only 3 mg / mL of the target polypeptide were treated with the above method as control samples. The GPC spectrum measured by gel permeation chromatography (GPC) analysis is shown in FIG. Fig.10 ,As can be seen from the figure, there is no change in its enzymatic hydrolysis pattern within 24 hours, and no obvious ,enzymatic degradation was observed within 24 hours.
[0124] Embodiment 6:
[0125] Take 200mg (0.4mmol) of the first monomer (its structural formula is shown in Formula I), add thioctic acid in molar ratios of 1:1, 5:1, 9:1, 19:1, 45:1, 96:1 and 166:1 respectively, and then add EDC.HCl (150mg) and HOBt (110mg). After adding about 2mL of anhydrous DMF to the system, seal it with a rubber stopper, introduce nitrogen bubbling for 30min, and then react for 6h at room temperature in a closed manner. After the reaction is completed, add about 18mL of anhydrous ether precipitation to the reaction system, and after being still for about 20min, remove the solvent to obtain zwitterionic polypeptides with alternating glutamic acid and lysine residues of thioctic acid-capped undeprotected groups.
[0126] The molecular weights of the polycondensation products obtained by gel permeation chromatography (GPC) analysis with DMF as the mobile phase were 5K, 7K, 8K, 9.5K, 11.6K, 16.1K and 18.1K Daltons ( Fig.11 ). After deprotection, the amino-terminated zwitterionic polypeptides with lipoic acid groups (structural formula as Formula XV, n:m=0:1) were obtained, and the molecular weights were 2.5K, 3.5K, 4.2K, 5K, 6K, 8.3K and 9.3K, respectively. This example proves that the molecular weight of the polypeptide can be regulated by adjusting the molar ratio of the monomer and the capping agent.
[0127] Embodiment 7:
[0128] 1) Polycondensation
[0129] Take 200mg (0.4mmol) of the first monomer (its structural formula is shown in Formula I), add EDC.HCl (115mg, 0.6mmol) and HOBt (81mg, 0.6mmol), and then add end-capping agent thioctic acid in a molar ratio of 20:1, 40:1, and 200:1 respectively according to the ratio of the first monomer to thioctic acid. After adding about 2mL of anhydrous N, N-diformamide (DMF) to the system, seal it with a rubber stopper, introduce nitrogen bubbling for 30min, and then react at room temperature for 48h. After the reaction is completed, add about 18mL of anhydrous ether precipitation to the reaction system, and after being static for about 20min, the solvent is removed to obtain three molecular weights of thioctic acid-terminated zwitterionic polypeptides with alternating glutamic acid and lysine residues without deprotection groups.
[0130] 2) Deprotection
[0131] After the above oil is completely dissolved with about 2 mL of trifluoroacetic acid (TFA), about 2 mL of 33% (33 wt.%) hydrobromic acid / acetic acid (HBr / HOAc) solution is added for deprotection. The reaction system will become turbid in about 1 hour. After about 3 hours of reaction, 25 mL of anhydrous ether is added to the reaction system to precipitate the product. After decanting the solution, about 10 mL of anhydrous ether is added to wash again. After the deprotected polypeptide is completely dissolved with distilled water, it is neutralized to neutrality with a saturated NaHCO3 solution, and then the solution is transferred to a dialysis bag with a molecular weight cutoff of 1000 (MWCO=1000) and dialyzed for 2-3 days. The obtained solution is frozen and vacuum dried to obtain a white solid product, which is a lipoic acid amino-terminated zwitterionic polypeptide (structural formula is shown in Formula XV, n:m=0:1), with molecular weights of 2.8 kDa, 5.4 kDa, and 12.0 kDa, respectively.
[0132] 3) Material resistance to nonspecific protein adsorption
[0133] The gold sheet was washed with ethanol and deionized water, dried, and the process was repeated twice; then it was placed in a UV cleaner for cleaning for 20 minutes. It was washed again with ethanol and deionized water twice, dried, and immersed in phosphate buffer (PBS pH 7.4) of three different molecular weight polypeptides capped with 2 mg / mL lipoic acid groups and cultured for 48 hours. It was taken out again, rinsed with deionized water for another 5 times, and dried. The nonspecific protein adsorption of the obtained gold sheet with polypeptide self-assembled monolayer (SAMs) was measured by HRP-labeled sheep anti-human immunoglobulin (anti-IgG / HRP) and fibrinogen (fibrinogen, Fg) combined with HRP-labeled fibrinogen antibody. The TCPS surface was used as a control, and the amount of protein adsorbed on the TCPS surface was set to 100%. The detailed operation process is as follows: the sample to be tested was first cultured with anti-IgG (1μg / mL) or Fg (10μg / mL) for 20 minutes, and then rinsed with PBS to remove all unadsorbed proteins. For Fg, it is also necessary to use HRP-labeled fibrinogen (anti-Fg / HRP) antibody to determine its adsorption amount. The sample adsorbed with Fg was then incubated with 10μg / mL HRP-labeled fibrinogen antibody (anti-Fg / HRP) for 20 minutes, and then rinsed with PBS to remove all unadsorbed proteins. Thereafter, all samples to be tested and TCPS controls were placed in 24-well plates, and 1mL of 1mg / mL o-phenylenediamine (OPD) citric acid buffer solution (0.1M, pH 5.0, containing 0.03% hydrogen peroxide) was injected into each well. After 20 minutes of color development, 1mL of 2N H2SO4 was added to each well to quench the enzyme activity. The absorbance of each well at 492nm was measured by an enzyme reader, and the relative amount of protein adsorption was calculated per unit area.
[0134] Test results such as Fig.12 As shown in the figure, as the molecular weight increases from 2.8kDa to 12.0kDa, the relative adsorption of anti-IgG and Fg also increases from 5.1±1.6%, 7.3±1.8% to 11.6±5.6%, 15.2±3.2%, respectively. Moreover, it can be clearly seen from the figure that for all test samples with the same molecular weight, the adsorption of Fg is higher than that of anti-IgG, but in general, the three peptides with different molecular weights have excellent anti-nonspecific protein adsorption capabilities.
[0135] Embodiment 8:
[0136] 1) Polycondensation
[0137] Take 200mg (0.4mmol) of the second monomer (its structural formula is shown in formula III), add EDC.HCl (153mg, 0.8mmol) and HOBt (108mg, 0.8mmol), and then add end-capping agent thioctic acid according to the molar ratio of the second monomer to thioctic acid of 20:1, 40:1, and 250:1. After adding about 2mL of anhydrous DMF to the system, seal it with a rubber stopper, introduce nitrogen bubbling for 30min, and then react for 40h at room temperature. After the reaction is completed, add about 18mL of anhydrous ether precipitation to the reaction system, and after standing for about 20min, remove the solvent to obtain an oily polypeptide containing thioctic acid group without deprotection group polymerized by the second monomer.
[0138] 2) Deprotection
[0139] After the above oil is completely dissolved with about 2 mL of trifluoroacetic acid (TFA), about 2 mL of 33% (33 wt.%) hydrobromic acid / acetic acid (HBr / HOAc) solution is added for deprotection. The reaction system will become turbid in about 1 hour. After about 3 hours of reaction, 25 mL of anhydrous ether is added to the reaction system to precipitate the product. After decanting the solution, about 10 mL of anhydrous ether is added to wash again. After the deprotected polypeptide is completely dissolved with distilled water, it is neutralized to neutrality with a saturated NaHCO3 solution, and then the solution is transferred to a dialysis bag with a molecular weight cutoff of 1000 (MWCO=1000) and dialyzed for 2-3 days. The obtained solution is frozen and vacuum dried to obtain a white solid product, which is a thioctic acid amino-terminated zwitterionic polypeptide (structural formula is shown in Formula XV, n:m=1:0), with molecular weights of 3.5 kDa, 5.6 kDa and 13.7 kDa, respectively.
[0140] 3) Material resistance to nonspecific protein adsorption
[0141] The gold sheet was washed with ethanol and deionized water, dried, and the process was repeated twice; then it was placed in a UV cleaner for cleaning for 20 minutes. It was washed again with ethanol and deionized water twice, dried, and immersed in phosphate buffer (PBS pH 7.4) of three different molecular weight polypeptides capped with 2 mg / mL lipoic acid groups and cultured for 48 hours. It was taken out again, rinsed with deionized water for another 5 times, and dried. The nonspecific protein adsorption of the obtained gold sheet with polypeptide self-assembled monolayer (SAMs) was measured by HRP-labeled sheep anti-human immunoglobulin (anti-IgG / HRP) and fibrinogen (fibrinogen, Fg) combined with HRP-labeled fibrinogen antibody. The TCPS surface was used as a control, and the amount of protein adsorbed on the TCPS surface was set to 100%. The detailed operation process is as follows: the sample to be tested was first cultured with anti-IgG (1μg / mL) or Fg (10μg / mL) for 20 minutes, and then rinsed with PBS to remove all unadsorbed proteins. For Fg, it is also necessary to use HRP-labeled fibrinogen (anti-Fg / HRP) antibody to determine its adsorption amount. The sample adsorbed with Fg was then incubated with 10μg / mL HRP-labeled fibrinogen antibody (anti-Fg / HRP) for 20 minutes, and then rinsed with PBS to remove all unadsorbed proteins. Thereafter, all samples to be tested and TCPS controls were placed in 24-well plates, and 1mL of 1mg / mL o-phenylenediamine (OPD) citric acid buffer solution (0.1M, pH 5.0, containing 0.03% hydrogen peroxide) was injected into each well. After 20 minutes of color development, 1mL of 2N H2SO4 was added to each well to quench the enzyme activity. The absorbance of each well at 492nm was measured by an enzyme reader, and the relative amount of protein adsorption was calculated per unit area.
[0142] Test results such as Fig.13 As shown. Fig.13 As can be seen, as the molecular weight increases from 3.5kDa to 13.7kDa, the relative adsorption of anti-IgG and Fg increases from 3.3±1.8%, 4.4±1.6% to 11.6±2.8%, 15.9±5.6%, respectively. For all the tested samples, the relative adsorption of Fg is higher than that of anti-IgG, which may be related to the additional adsorption caused by the larger volume, loose structure and easy denaturation of Fg. In general, the three peptides with different molecular weights have excellent anti-nonspecific protein adsorption ability.
[0143] Embodiment 9:
[0144] 1) Polycondensation
[0145] Take 100mg (0.2mmol) of the first monomer (its structural formula is shown in Formula I) and 100mg (0.2mmol) of the second monomer (its structural formula is shown in Formula III), add EDC.HCl (115mg, 0.6mmol) and HOBt (81mg, 0.6mmol), then add end-capping agent thioctic acid according to the molar ratio of the total molar amount of the first monomer and the second monomer to thioctic acid of 20:1, 40:1, 200:1. After adding about 2mL of anhydrous N, N-diformamide (DMF) to the system, seal it with a rubber stopper, pass nitrogen bubbling for 30min and then react at room temperature for 36h. After the reaction is completed, add about 18mL of anhydrous ether precipitation to the reaction system, and after being static for about 20min, remove the solvent to obtain three oily polypeptides containing thioctic acid groups without deprotection groups.
[0146] 2) Deprotection
[0147] After the above oil is completely dissolved with about 2 mL of trifluoroacetic acid (TFA), about 2 mL of 33% (33 wt.%) hydrobromic acid / acetic acid (HBr / HOAc) solution is added for deprotection. The reaction system will become turbid in about 1 hour. After about 3 hours of reaction, 25 mL of anhydrous ether is added to the reaction system to precipitate the product. After decanting the solution, about 10 mL of anhydrous ether is added to wash again. After the deprotected polypeptide is completely dissolved with distilled water, it is neutralized to neutrality with a saturated NaHCO3 solution, and then the solution is transferred to a dialysis bag with a molecular weight cutoff of 1000 (MWCO=1000) and dialyzed for 2-3 days. The obtained solution is frozen and vacuum dried to obtain a white solid product, which is a lipoic acid amino-terminated zwitterionic polypeptide (structural formula is shown in Formula XV, n:m=1:1), with molecular weights of 3.2 kDa, 5.4 kDa and 12.8 kDa, respectively.
[0148] 3) Material resistance to nonspecific protein adsorption
[0149] The gold sheet was washed with ethanol and deionized water, dried, and the process was repeated twice; then it was placed in a UV cleaner for cleaning for 20 minutes. It was washed again with ethanol and deionized water twice, dried, and immersed in phosphate buffer (PBS pH 7.4) of three different molecular weight polypeptides capped with 2 mg / mL lipoic acid groups and cultured for 48 hours. It was taken out again, rinsed with deionized water for another 5 times, and dried. The nonspecific protein adsorption of the obtained gold sheet with polypeptide self-assembled monolayer (SAMs) was measured by HRP-labeled sheep anti-human immunoglobulin (anti-IgG / HRP) and fibrinogen (fibrinogen, Fg) combined with HRP-labeled fibrinogen antibody. The TCPS surface was used as a control, and the amount of protein adsorbed on the TCPS surface was set to 100%. The detailed operation process is as follows: the sample to be tested was first cultured with anti-IgG (1μg / mL) or Fg (10μg / mL) for 20 minutes, and then rinsed with PBS to remove all unadsorbed proteins. For Fg, it is also necessary to use HRP-labeled fibrinogen (anti-Fg / HRP) antibody to determine its adsorption amount. The sample adsorbed with Fg was then incubated with 10μg / mL HRP-labeled fibrinogen antibody (anti-Fg / HRP) for 20 minutes, and then rinsed with PBS to remove all unadsorbed proteins. Thereafter, all samples to be tested and TCPS controls were placed in 24-well plates, and 1mL of 1mg / mL o-phenylenediamine (OPD) citric acid buffer solution (0.1M, pH 5.0, containing 0.03% hydrogen peroxide) was injected into each well. After 20 minutes of color development, 1mL of 2N H2SO4 was added to each well to quench the enzyme activity. The absorbance of each well at 492nm was measured by an enzyme reader, and the relative amount of protein adsorption was calculated per unit area.
[0150] Test results such as Fig.14 As shown. As can be seen from the figure, as the molecular weight increases from 3.2kDa to 12.8kDa, the relative adsorption of anti-IgG and Fg increases from 3.8±1.6%, 5.6±1.6% to 11.4±4.8%, 15.5±3.2%, respectively. For all the tested samples, the relative adsorption of Fg is higher than that of anti-IgG, which may be related to the additional adsorption caused by the larger volume, loose structure and easy denaturation of Fg. In general, the three peptides with different molecular weights have excellent anti-nonspecific protein adsorption ability.
[0151] Embodiment 10:
[0152] 1) Polycondensation
[0153] Take 100 mg (0.2 mmol) of the first monomer (whose structural formula is shown in Formula I) and 100 mg (0.2 mmol) of the second monomer (whose structural formula is shown in Formula III), add EDC.HCl (115 mg, 0.6 mmol) and HOBt (81 mg, 0.6 mmol), and then add the capping agent mercapto trityl protected cysteamine according to the molar ratio of the total molar amount of the first monomer and the second monomer to the mercapto trityl protected cysteamine of 20:1, 40:1, 200:1. After adding about 2 mL of anhydrous N, N-diformamide (DMF) to the system, seal it with a rubber stopper, introduce nitrogen bubbling for 30 minutes, and then react at room temperature for 36 hours. After the reaction is completed, add about 18 mL of anhydrous ether precipitation to the reaction system, let it stand for about 20 minutes, and then pour off the solvent to obtain mercapto trityl protected cysteamine end-capped polypeptides of three molecular weights without deprotection groups.
[0154] 2) Deprotection
[0155] After the above oil is completely dissolved with about 2 mL of trifluoroacetic acid (TFA), about 2 mL of 33% (33 wt.%) hydrobromic acid / acetic acid (HBr / HOAc) solution is added for deprotection. The reaction system will become turbid in about 1 hour. After about 3 hours of reaction, 25 mL of anhydrous ether is added to the reaction system to precipitate the product. After decanting the solution, about 10 mL of anhydrous ether is added to wash again. After the deprotected polypeptide is completely dissolved with distilled water, it is neutralized to neutrality with a saturated NaHCO3 solution, and then the solution is transferred to a dialysis bag with a molecular weight cutoff of 1000 (MWCO=1000) and dialyzed for 2-3 days. The obtained solution is frozen and vacuum dried to obtain a white solid product, which is a cysteamine carboxyl-terminated zwitterionic polypeptide (structural formula as shown in Formula XXIII, n:m=1:1) with molecular weights of 3.4 kDa, 5.6 kDa and 13.1 kDa respectively.
[0156] 3) Material resistance to nonspecific protein adsorption
[0157] The gold sheet was washed with ethanol and deionized water, dried, and the process was repeated twice; then it was placed in a UV cleaner for cleaning for 20 minutes. It was washed again with ethanol and deionized water twice, dried, and immersed in phosphate buffer (PBS pH 7.4) of three different molecular weight polypeptides capped with 2 mg / mL lipoic acid groups and cultured for 48 hours. It was taken out again, rinsed with deionized water for another 5 times, and dried. The nonspecific protein adsorption of the obtained gold sheet with polypeptide self-assembled monolayer (SAMs) was measured by HRP-labeled sheep anti-human immunoglobulin (anti-IgG / HRP) and fibrinogen (fibrinogen, Fg) combined with HRP-labeled fibrinogen antibody. The TCPS surface was used as a control, and the amount of protein adsorbed on the TCPS surface was set to 100%. The detailed operation process is as follows: the sample to be tested was first cultured with anti-IgG (1μg / mL) or Fg (10μg / mL) for 20 minutes, and then rinsed with PBS to remove all unadsorbed proteins. For Fg, it is also necessary to use HRP-labeled fibrinogen (anti-Fg / HRP) antibody to determine its adsorption amount. The sample adsorbed with Fg was then incubated with 10μg / mL HRP-labeled fibrinogen antibody (anti-Fg / HRP) for 20 minutes, and then rinsed with PBS to remove all unadsorbed proteins. Thereafter, all samples to be tested and TCPS controls were placed in 24-well plates, and 1mL of 1mg / mL o-phenylenediamine (OPD) citric acid buffer solution (0.1M, pH 5.0, containing 0.03% hydrogen peroxide) was injected into each well. After 20 minutes of color development, 1mL of 2N H2SO4 was added to each well to quench the enzyme activity. The absorbance of each well at 492nm was measured by an enzyme reader, and the relative amount of protein adsorption was calculated per unit area.
[0158] Test results such as Fig.15 As shown. As can be seen from the figure, as the molecular weight increases from 3.4kDa to 13.1kDa, the relative adsorption of anti-IgG and Fg increases from 4.2±1.2%, 6.0±1.7% to 12.0±3.8%, 16.2±3.2%, respectively. For all the tested samples, the relative adsorption of Fg is higher than that of anti-IgG, which may be related to the additional adsorption caused by the larger volume, loose structure and easy denaturation of Fg. In general, the three peptides with different molecular weights have excellent anti-nonspecific protein adsorption ability.
[0159] The specific implementation modes of the present invention are described above in conjunction with the accompanying drawings, but it is obvious that the present invention is not limited to the above embodiments, and any changes and modifications based on the claims of the present invention are within the protection scope of the present invention.
Claims
1. A polypeptide having controllable enzymatic degradation and resistant to non-specific protein adsorption, characterized in that: Having a structure as shown in any one of Formula VII to Formula XIV: In the above formulae, m and n represent the degree of polymerization of the monomer, and m and n are integers greater than 0; The anti-nonspecific protein adsorption polypeptide is used to adjust the ratio of m and n so that the enzyme degradation time meets the requirements of specific applications.
2. The polypeptide according to claim 1, characterized in that Its structural formula is shown in any one of Formula XV to Formula XXX: Among them, R1 is a carboxylic acid group containing a selective reactive group for functional modification after deprotection, and R2 is an amino group containing a selective reactive group for functional modification after deprotection.
3. The polypeptide according to claim 2, characterized in that: R1 is a lipoic acid group, or a cysteine group connected to a carboxyl group on cysteine; R2 is a cysteamine group, or a cysteine group connected to an amino group on cysteine.
4. A method for preparing the polypeptide according to claim 1, characterized in that: include: Carrying out a polycondensation reaction between the first monomer and the second monomer, and carrying out a deprotection treatment on the polycondensate to obtain the polypeptide, wherein the molar ratio of the first monomer to the second monomer is m:n, and m and n are respectively integers greater than 0; The first monomer has a structure as shown in Formula I or Formula II, and the second monomer has a structure as shown in Formula III, Formula IV, Formula V or Formula VI:
5. The preparation method according to claim 4, characterized in that: The reaction system of the polycondensation reaction contains an amino end-capping agent or a carboxyl end-capping agent.
6. The preparation method according to claim 5, characterized in that: The amino end-capping agent is a carboxylic acid containing a thiol group after deprotection.
7. The preparation method according to claim 6, characterized in that: The amino end blocking agent is lipoic acid or a cysteine derivative, and the cysteine derivative contains an amino group protected by a benzyloxycarbonyl group and a thiol group protected by a trityl group.
8. The preparation method according to claim 5, characterized in that: The carboxyl end capping agent is an amine containing a thiol group after deprotection.
9. The preparation method according to claim 8, characterized in that: The carboxyl end capping agent is cysteamine protected by mercaptotriphenylmethyl, or cysteine protected by carboxybenzyl and mercaptotriphenylmethyl.
Citation Information
Patent Citations
Invisible polypeptide with good non-specific protein absorption resistance performance and preparation method thereof
CN104926923A
